Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Dec;23(3-4):104-6.
doi: 10.1007/s12288-008-0007-x. Epub 2008 Mar 19.

Cefepime versus ceftazidime as empirical therapy for fever in neutropenic patients with haematological malignancies

P S Ghalaut  1 , Uma Chaudhry, Veena Singh Ghalaut, Sameer Aggarwal, Vinny Sood, Gaurav Dixit
Affiliations

Cefepime versus ceftazidime as empirical therapy for fever in neutropenic patients with haematological malignancies

P S Ghalaut et al. Indian J Hematol Blood Transfus. 2007 Dec.

Abstract

An open randomized comparative study was conducted to evaluate the efficacy of Cefepime (2 gm iv. 8 hr.) vs. ceftazidime (2 gm iv. every 8 hr.) in empirical therapy of febrile neutropenic patients. A total of 40 eligible febrile episodes were randomized to be treated with study regimen. Twenty febrile episodes were treated with cefepime and 20 were treated with ceftazidime. The two groups were comparable in terms of age, sex, height, underlying neoplasm, number of pretherapy neutrophils, duration of neutropenia. The overall therapeutic success rate of cetepime group (60%) was comparable to that of ceftazidime group (55%). The results of this study suggest that cefepime is an effective and safe agent in empirical therapy of febrile episode in neutropenic patient and its efficacy is comparable with that of ceftazidime.

PubMed Disclaimer

References

    1. Bergumans T., Scolier S.P. Myelosuppression and infective complications. In: Souhami R.L., Tannok I., Hohznberger P., Horiot S.C., editors. Oxford Textbook of oncology. 2. New York: Oxford University Press Inc.; 2002. pp. 575–89.
    1. Finberg R. Infections in patients with cancer. In: Kasper D.L., Braunwald E., Fauci A.S., Hauser S.L., Longo D.L., Jameson J.L., editors. Harrison’s Principles of Internal Medicine. Vol.1. 16. New York: McGraw Hill; 2005. pp. 489–496.
    1. Wang F., Liu C. Y., Hsu H. C., Gau I. P., Chan W. K., Haung M. L. A comparative study of Cefepime versus Ceftezadime as empirical therapy in febrile neutropenic patients. Chemotherapy. 1999;45:370–379. doi: 10.1159/000007228. - DOI - PubMed
    1. Jandula B., Martino R., Gurgi M., Manteiga R., Sierra J. Treatment of febrile neutropenia with cefepime monotherapy. Chemotherapy. 2001;47:226–231. doi: 10.1159/000063226. - DOI - PubMed
    1. Kebudi R., Gorgun O., Ayan I., Gurler N., Akici F., Toreci K. Randomized comparison of cefepime versus Ceftezadime monotherapy for fever and neutropenia in children with solid tumours. Med Pediatr Oncol. 2001;36(4):434–441. doi: 10.1002/mpo.1107. - DOI - PubMed

LinkOut - more resources